Skip to main content

AP24534 (Ponatinib) | Abl, Src, FGFR, VEGFR inhibitor

$109.00
Write a Review
SKU:
C2724-5
Bulk Pricing:
Buy in bulk and save
Adding to cart… The item has been added

Ponatinib (AP24534) is a imidazopyridine-based pan-inhibitor of the kinases Abl, Abl(T315I), and other clinically important Abl kinase domain mutants at potencies of 0.37 nM, 2.0 nM, and 0.30-0.44 nM, respectively. Ponatinib also potently inhibits Src, VEGFR, FGFR, and PDGFR at 5.4, 1.5, 22, and 1.1 nM, respectively, while being >1000-fold selective over IGF-1R, Aurora A, andCDK2/Cyclin E. [1] In contrast to first- (imatinib) and second-line therapies (nilotinib, dasatinib) for CML, Ponatinib shows inhibition against the T31I mutant of Bcr-Abl.

In a panel of leukemic cell lines containing activating mutations in Flt3, Kit, or activating fusions of FGFR, PDGFRa, EOL1, and KG-1, Ponatinib inhibited phosphorylation of all four receptor tyrosine kinases in a dose dependent manner with IC50 values between 0.3 and 20 nM. [2] Apoptotic induction is believed to be the mechanism by which Ponatinib inhibits FLT3-ITD to in turn inhibit MV4-11 cell viability. [2]


Technical information:

Chemical Formula:   C29H27F3N6O
CAS #:   943319-70-8
Molecular Weight:   532.57
Purity:   >98%
Appearance:   White
Chemical Name:   3-(2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   AP-24534, AP24534, Ponatinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. O'Hare et al., AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Res. 2009, 16(5), 401-412. Pubmed ID: 19878872
2. Gozgit et al., Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer. Ther. 2011, 10, 1028-1035. Pubmed ID: 21482694

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.